Position in VTGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$299
-$48 QoQ
Shares Held
526
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in VTGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MAI Capital Management holds $23,626,176 across 53 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
6,715 | $4,187,071 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,638 | $2,800,563 | |
| 3 | DNLI |
Denali Therapeutics Inc.
|
49,160 | $1,264,394 | |
| 4 | INCY |
Incyte Corp
|
10,126 | $1,147,882 | |
| 5 | TRVI |
Trevi Therapeutics, Inc.
|
56,130 | $1,046,824 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
5,147 | $963,929 | |
| 7 | LGND |
Ligand Pharmaceuticals Inc
|
2,963 | $936,574 | |
| 8 | EXEL |
Exelixis, Inc.
|
13,982 | $760,760 |
All Filings in VTGN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $299 | 526 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $347 | 526 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,867 | 526 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $1,052 | 526 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $1,440 | 576 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,796 | 609 | Shares | Sole | 2025-02-14 | |
| 2023-03-31 | $70,190 | 584,925 | Shares | Sole | 2023-05-10 | |
| 2022-12-31 | $61,773 | 617,733 | Shares | Sole | 2023-02-09 | |
| 2022-09-30 | $278,047 | 1,853,650 | Shares | Sole | 2022-11-15 | |
| 2022-06-30 | $2,342,030 | 2,661,398 | Shares | Sole | 2022-07-19 | |
| No filing history on record for this holder in this stock. | ||||||